Novartis has provided Monte Rosa Therapeutics with a $50 million milestone payment following the dosing of the first patient in a VAV1‑targeted drug trial.
Further verified details were not immediately available.
Novartis hands Monte Rosa Therapeutics $50M milestone after first patient dosing
Novartis has paid Monte Rosa Therapeutics $50 million as a milestone after the first patient was dosed in a VAV1‑targeted drug trial.
PA
Priya Anand · Equities & Earnings Desk · 13 Sept 2026 · 10:14 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →
